This is an incredibly exciting time in the biopharmaceutical industry – where we’re seeing unparalleled medical advances across a broad range of therapeutic areas that are revolutionizing how certain diseases are diagnosed, treated and, in some cases, cured. Biopharmaceutical innovation is ushering in a new era of medical treatment that is transforming patient lives though breakthrough science, precision medicines, and first-in-class therapies that represent entirely new approaches to treating disease.
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of primary and specialty care medicines that transform lives. Our primary focus is on four important areas of healthcare: Cardiovascular and Metabolic disease; Oncology; Respiratory, Inflammation and Autoimmunity; and Rare Diseases. For more information: www.astrazeneca.ca.
The Canadian Frailty Network (CFN) is Canada’s sole network devoted to improving care for older Canadians living with frailty and supporting their families and caregivers. We do this by increasing frailty recognition and assessment, increasing evidence for decision-making, advancing evidence-based changes to care, training the next generation of care professionals and scientists, catalyzing change in Canada’s health and social care systems, and always engaging with older adults and their families and caregivers.
Frailty today is as important as Medicare was in the 1960s – a topic central to healthcare in Canada.
Dr. Duncan Sinclair, Past Board Member, CFN and Former Dean, Faculty of Medicine, Queens University
Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.
The member companies of Innovative Medicines Canada have a strong history of success in discovering, developing and delivering medicines and vaccines that Canadians need to live healthy and productive lives. We have, over time and as a country, prioritized innovative health research within the health care system, with the effect of creating an environment that allows our best and brightest to do their complex and important work. We want to work with all levels of government will continue to support life sciences research in Canada through effective and thoughtful public policy. This includes developing policies and programs that ensure Canadians have access to new medicines, when they need them.
Pamela Fralick, President, Innovative Medicines Canada
The COVID-19 pandemic has had devastating consequences for older adults, especially those living with dementia, and their caregivers. Research from Baycrest and elsewhere suggests that both direct and indirect impacts of COVID-19 on the brain may lead to an increase in the incidence of dementia. Now more than ever, government support of research and innovation in aging, brain health, and dementia is imperative. There is a critical need for significant investment both in foundational research to further our understanding of aging and the human brain, and in translation and innovation programs to develop, spread, and scale novel approaches that prevent, detect, and treat dementia. Together, we can create a world in which everyone is empowered to fear no age.
Dr. Allison Sekuler, VP Research, Baycrest and Managing Director, Baycrest′s Rotman Research Institute
Baycrest’s Rotman Research Institute advances our understanding of human brain structure and function in critical areas of cognitive neuroscience, including perception, memory, language, attention, and decision making. With a primary focus on aging and brain health, RRI scientists and trainees, and other researchers across Baycrest, promote effective care and improved quality of life for older adults through research into age- and disease-related behavioural and neural changes.
BioCanRx is Canada’s Immunotherapy Network. Our vision is to cure patients and enhance the quality of life of those living with cancer. We invest in leading edge immune oncology research translating world-class technologies from the lab into early phase clinical trials. BioCanRx is the only national not-for-profit network composed of academic health centres focused on connecting and aligning research investments, expertise, infrastructure, skills training, biomanufacturing and private sector partnerships to bring novel made-in-Canada immunotherapies to patients.
Canada’s science infrastructure is challenged to move discoveries from the lab to clinical trials. Many of our inventions become targets of foreign takeovers. By addressing the challenges that hamper translation, we‘ll be better situated to advance made-in-Canada innovations like vaccines and immunotherapies. BioCanRx urges all parties to support predictable, long-term investments for preclinical to clinical development of therapies for the benefit of patients and the economy.
Dr. Stéphanie Michaud, President and CEO, BioCanRx
Bruyère Research Institute aims to find new ways to maximize quality of life and help people stay and return home. Through an equity lens, we focus on global aging and improving care and the health system by proudly partnering with industry, academia, government, and patient/family-led groups. Leveraging research and innovation, we pursue advancements in technology for aging in place, virtual rehabilitation, and supporting hospital to home transitions for older adults.
Older adults and long-term care residents have seen devastating impacts this past year. When Canadians ask ‘what next?’ we need to be prepared to offer solutions backed by best evidence and practice. Research and innovation are the backbone of health care progress, feeding into care and economy alike. If we want to see real-world impact, we need to continue investing in the people and the science that are improving health outcomes for Canadians. The Bruyère Research Institute is dedicated to collaborating with industry and government to address the needs of our aging population.
Dr. Heidi Sveistrup, CEO and Chief Scientific Officer, Bruyère Research Institute
GlycoNet is a pan-Canadian network focusing on glycomics–the study of carbohydrates in biological systems–to deliver tangible, made-in-Canada glycomics-based solutions to critical global health issues. GlycoNet develops vaccines, therapeutics, diagnostics, and enabling technologies for infectious, chronic, and neurodegenerative diseases. As a one-stop destination for glycomics research and commercialization, GlycoNet leverages the expertise from researchers, clinicians, and industry partners to accelerate health innovations, support Canadian entrepreneurs, and develop skilled talents. For more information, visit glyconet.ca.
Science is a critical economic driver, as is health of population. COVID-19 pandemic is giving us ample evidence. As we build back our capacity, there will be need for new standards of health security and new expectations. Glycomics can offer new avenues to drug discovery, novel methods of biomanufacturing, and more personalized healthcare. The breakthroughs achieved by GlycoNet researchers are addressing the key gap in Canadian health research infrastructure – developing, translating, and commercializing research to realize its full economic potential. As we bring new areas of science to fruition, we make a more sustainable world for future generations with the help of glycomics-based vaccines, therapeutics, and diagnostics.
Dr. Elizabeth Nanak, Chief Executive Officer, GlycoNet
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights, help Roche deliver truly personalized healthcare. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
The current global health crisis has only reinforced the importance of strengthening life sciences, especially here in Canada. Roche is committed to continuing our investments in the Canadian healthcare ecosystem and being a trusted partner in building a strong life sciences sector to solidify Canada’s position as a leader when it comes to innovation.
Ronnie Miller, President and CEO, Roche Canada
Ryerson University is one of Canada’s largest comprehensive universities and a leader in innovative, career-oriented education. Here, learning and experience go hand-in-hand. What our students study in the classroom is enhanced by real-world knowledge and informed by our mission to serve societal needs. Located in the heart of Toronto, the university’s distinctly urban character and focus on experiential learning and entrepreneurship place it in a unique position to make an impact locally and across the globe.
Our university has a long track record of making and responding to change. Through building partnerships across industries, leading experiential learning programs or committing to advance equity and inclusion, we believe in challenging the status quo in pursuit of new possibilities. I couldn’t be more excited about our plans to launch a new kind of medical school, where we can create a new model for primary care — one that’s community-driven, intentionally inclusive and that trains doctors whose cultural awareness and humility are as crucial as their medical skills.
Dr. Mohamed Lachemi, President & Vice Chancellor, Ryerson University
The Health Charities Coalition of Canada is a member-based organization of national health charities and patient groups dedicated to improving health policy and promoting the highest quality health research. Our members provide leadership on major health issues and work to bring about sustainable change in improving the health and well-being of Canadians.
Health charities play an important and complementary role to other research funders, filling essential gaps, promoting patient-centered research and providing direct connections to patient communities. As our sector recovers from the impact of the COVID-19 pandemic, Canadians living with diseases and/or medical conditions will continue to turn to science and ground-breaking research to identify new and innovative approaches to the challenges they face. Critical federal support is needed to stabilize and grow Canada’s health research and innovation system.
Connie Côté, Chief Executive Officer, Health Charities Coalition of Canada
Mood Disorders Society of Canada (MDSC) has evolved as one of Canada’s best-connected mental health Non-Governmental Organizations (NGO) with a demonstrated track record for forging and maintaining meaningful and sustained partnerships with the public, private and non-profit sectors throughout Canada.
Mood Disorders Society of Canada (MDSC) is dedicated to working tirelessly on behalf of the patient and family community to tackle mental illness and to ensure our priorities and experiences are consistently brought to the forefront. Known for our collaborative approach in driving research and advocating for policy improvements, MDSC supports community mental health organizations, programs and services, from coast to coast. This is an unprecedented time in mental health where we are seeing the ramifications of the pandemic create even more mental health problems and crises. We must actively pursue investments for innovation in therapies and empower collaborative programs and services. At MDSC, we strive to bring together all community stakeholders including health care, research, professionals, and government with the patient community to work together to fight mental illness and improve mental wellness.
Dave Gallson, National Executive Director, Mood Disorders Society of Canada
Lakehead University is a comprehensive, research-intensive university with two campuses in Orillia and Thunder Bay, Ontario. As the only university in Northwestern Ontario, we serve a geographical catchment area the size of France, including almost 80% of Ontario’s First Nations communities. For five years in a row (2015-2019), Research Infosource ranked Lakehead University Canada’s #1 Research University in our peer category. In 2021, Maclean’s ranked Lakehead second in total research funding.
Lakehead University’s 2019-2024 Research Plan includes Health and Well-Being as one of five research priorities. Our researchers aim to make a difference in the health and well-being of our communities across the age and health continuum, including rural and remote health, addictions and mental health, and medical imaging. We are making significant advances in health research to positively impact those living in Northern Ontario’s remote and rural communities.
Dr. Andrew Dean, VP Research and Innovation, Lakehead University
A member of the prestigious U15 group of Canadian research universities, Queen’s University has a long history of discovery and innovation that has shaped our knowledge and helped address some of the world’s most pressing questions, including issues around environmental protection, health care, and the development of advanced technologies.
Through our work with collaborators, communities, governments, and industry, Queen’s University continues to advance research and drive knowledge mobilization and innovation to make a measured impact on Canada and the world.